Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
131.07
+0.59 (0.45%)
At close: Jul 24, 2026, 4:00 PM EDT
130.99
-0.08 (-0.06%)
After-hours: Jul 24, 2026, 7:58 PM EDT
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$876,907
Profits / Employee
$119,133
Market Cap
323.72B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
MRK News
- 2 days ago - Merck announces initial access plans for alimatravir - TheFly
- 2 days ago - Merck licenses experimental HIV pill to generic makers in 129 countries - Reuters
- 2 days ago - Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development - Business Wire
- 4 days ago - Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
- 5 days ago - Gilead, Merck report ‘high’ rates of virologic suppression in ISLEND trials - TheFly
- 5 days ago - Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy - Business Wire
- 6 days ago - What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment. - Barrons
- 9 days ago - Use These ETFs as Health Stocks LLY, UNH, MRK Thrive - ETF Trends